Clinical trial · Interventional
Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
Pilot Study of UWNKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
NCT04717999CI-TRIAL-00049579unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy in patients with relapsed and/or refractory glioblastoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NKG2D CAR-T | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- UWN2D CAR-T
- interventionNames
- Biological: NKG2D CAR-T
Primary outcomes (1)
- measure
- Number of Participants who experience a Dose-Limiting Toxicity (DLT)
- timeFrame
- 2 years
- description
- Defined as the dose safely administered Intratumoral for the treatment of patients with GBM
Secondary outcomes (2)
- measure
- Overall Response Rate
- timeFrame
- 1 year
- description
- Defined as the proportion of subjects with overall response of either complete response (CR) or partial response (PR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed glioblastoma multiforme (GBM) and are at first or second relapse. * Hemoglobin ≥ 9.0 g/dl, absolute neutrophil count (ANC) ≥ 1,000 cells/µl, platelets ≥ 125,000 cells/µl * No active infection of HIV, HTLV and Syphilis * Adequate renal function * Adequate hepatic function * Adequate cardiac function * Adequate venous access for apheresis, and no other contraindications for leukapheresis * Voluntary informed consent is given. Exclusion Criteria: * Pregnant or lactating women. * Uncontrolled active infection. * History of hepatitis B or hepatitis C infection. * Previously treatment with any gene therapy products or cell therapy product in past 28 days. * Cannot undergo MRI with contrast or SPECT/CT * HIV infection. * Have autoimmune disorders * Have active infection or inflammatory disorders * Prescreening test results in expansion rate less than 5 folds * An allergy to gentamycin and/or streptomycin
References
Publications (0)
Data not yet available
No reference posted for this study.